Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Digital Engagement for Lifelong Health (DELPHI)

25 mai 2026 mis à jour par: Gennaro Tartarisco, Istituto per la Ricerca e l'Innovazione Biomedica

Digital Engagement for Lifelong Prevention and Health Improvement

The DELPHI project (Digital Engagement for Lifelong Prevention and Health Improvement) aims to develop, implement, and validate an advanced digital platform for promoting well-being and personalized prevention of chronic non-communicable diseases in healthy adults. By integrating wearable sensors, artificial intelligence, federated learning, and the Human Digital Twin (HDT) paradigm, the DELPHI platform is designed to collect, analyze, and interpret multidimensional data in order to deliver dynamic and personalized recommendations for healthy lifestyles.

The study adopts a multicenter, randomized controlled pilot design, with a maximum duration of 12 months per participant. A total of 200 healthy adults aged 18-65 will be recruited in Southern Italy (Sicily, Campania, and Basilicata) and randomly assigned to either: (1) an experimental group using the full DELPHI platform, including personalized recommendations, adaptive content, and continuous feedback; or (2) a control group using a basic version limited to passive monitoring.

As a non-clinical primary prevention pilot study, DELPHI aims to assess the operational feasibility, usability, and acceptability of the platform in real-world settings, while also exploring preliminary signals of impact on health and lifestyle domains without confirmatory purposes. Secondary objectives include monitoring physiological indicators, adherence to the app and wearable devices, and evaluating the feasibility of implementing the platform in workplace environments.

Data collection will rely on wearable devices, digital questionnaires, and behavioral analysis, with strong safeguards for personal data protection in compliance with GDPR and advanced security approaches such as federated learning and encryption.

Specific subgroups, including workers from the Fondazione Don Carlo Gnocchi (FDG) as well as university staff and students, will be involved in targeted assessments related to mental well-being and distress. In addition, workers from the FDG will test a virtual reality module designed to evaluate biomechanical overload risks during manual handling activities in simulated environments. These additional physiological and virtual reality components are exploratory and non-diagnostic.

Overall, DELPHI seeks to provide a solid foundation for the adoption of predictive and personalized models in digital health, contributing to the development of a sustainable and accessible prevention ecosystem, particularly in Southern Italy.

Aperçu de l'étude

Type d'étude

Interventionnel

Inscription (Estimé)

200

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Sauvegarde des contacts de l'étude

Lieux d'étude

      • Messina, Italie, 98164
        • Recrutement
        • Institute for Biomedical Research and Innovation (IRIB)-National Reasearch Council (CNR)
        • Sous-enquêteur:
          • Roberta Bruschetta
        • Sous-enquêteur:
          • Simona Campisi
        • Sous-enquêteur:
          • Maria Valeria Maiorana
        • Chercheur principal:
          • Gennaro Tartarisco
        • Sous-enquêteur:
          • Serena Iacono Isidoro
        • Sous-enquêteur:
          • Concetta Polizzi
        • Sous-enquêteur:
          • Renato Tino
        • Sous-enquêteur:
          • Marco Germanotta
        • Contact:
        • Sous-enquêteur:
          • Irene Aprile
        • Sous-enquêteur:
          • Mariacristina Siotto
        • Sous-enquêteur:
          • Alessandro Guerrini
        • Sous-enquêteur:
          • Monia Andrea Papa
        • Sous-enquêteur:
          • Giorgia Bruschetta
        • Sous-enquêteur:
          • Barbara Caci
        • Sous-enquêteur:
          • Maria Cocchiara
        • Sous-enquêteur:
          • Flavia Altavilla
        • Sous-enquêteur:
          • Alessia Valdesi
        • Sous-enquêteur:
          • Chiara Urone
        • Sous-enquêteur:
          • Giulia Giordano

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

  • Adulte
  • Adulte plus âgé

Accepte les volontaires sains

Oui

La description

Inclusion Criteria:

  • Apparent good general health status, confirmed by medical history and initial self-assessment.
  • Ability to understand the study information and provide informed consent.
  • Availability and motivation to participate for the entire duration of the study (12 months).
  • Access to a smartphone compatible with the DELPHI application.
  • Willingness to wear the wearable devices for continuous monitoring of physiological parameters.
  • Basic familiarity with mobile applications or willingness to receive training on their use.
  • Signed informed consent.

Exclusion Criteria:

  • Presence of severe chronic diseases in active phase (e.g., oncological, cardiovascular, or neurological diseases).
  • Acute or unstable conditions that could compromise participation in the protocol.
  • Current pregnancy.
  • Diagnosed major cognitive or psychiatric disorders that hinder understanding of or adherence to the protocol.
  • Current use of medications that significantly affect the parameters being monitored (e.g., psychotropic drugs, beta-blockers).
  • Simultaneous participation in other clinical studies.
  • Logistical difficulties that prevent frequent interaction with the platform (e.g., lack of connection, unwillingness to attend periodic follow-ups).

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: La prévention
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Experimental group
Participants will use the full version of the DELPHI platform, including wearable sensors, mobile app-based data collection, personalized recommendations generated through artificial intelligence algorithms, multimedia content (physical exercises, mindfulness activities, and educational videos), as well as interactive notifications and feedback.

the full version of the DELPHI digital platform, designed to support personalized primary prevention and health promotion. The intervention includes continuous monitoring through wearable sensors (Fitbit Inspire 3), mobile app-based data collection, and adaptive lifestyle recommendations generated by artificial intelligence algorithms within a Human Digital Twin framework.

Participants will receive personalized feedback and notifications related to physical activity, sleep, nutrition, hydration, stress management, and psychological well-being. The platform also delivers multimedia educational content, including guided exercises, mindfulness and breathing practices, wellness educational videos, and behavioral micro-actions. Data collected through wearable devices, digital questionnaires, and behavioral monitoring are used to dynamically tailor recommendations and preventive strategies throughout the study period.

Autre: Control group
Participants will access a limited version of the application restricted to passive monitoring functions only, without personalized recommendations, adaptive content, or interactive notifications.

Participants assigned to the control group will use a limited version of the DELPHI application restricted to passive monitoring functions. The application will collect data from wearable devices and questionnaires related to physical activity, sleep, nutrition, and well-being, but participants will not receive personalized recommendations, adaptive educational content, interactive feedback, or behavioral notifications.

The control condition is intended to provide observational digital monitoring only, without active preventive intervention or AI-based personalization.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
World Health Organization Quality of Life (WHOQoL)
Délai: Baseline and 6 months
The World Health Organization Quality of Life (WHOQoL) is a questionnaire used to assess quality of life.The WHOQOL-BREF, its short form, includes 26 items and evaluates four domains: physical health, psychological health, social relationships, and environment. It does not generate a single total score; instead, it provides separate domain scores, with higher values indicating better quality of life
Baseline and 6 months
Depression, Anxiety, and Stress Symptoms (DASS-21)
Délai: Baseline and 6 months

The Depression, Anxiety and Stress Scales-21 (DASS-21) is a 21-item self-report instrument designed to assess the severity of depression, anxiety, and stress symptoms. It consists of three subscales, each containing 7 items, and uses a 4-point response format. The scale provides separate scores for depression, anxiety, and stress rather than a single diagnostic score.

  • Depression: normal 0-9, mild 10-13, moderate 14-20, severe 21-27, extremely severe 28+.
  • Anxiety: normal 0-7, mild 8-9, moderate 10-14, severe 15-19, extremely severe 20+.
  • Stress: normal 0-14, mild 15-18, moderate 19-25, severe 26-33, extremely severe 34+.
Baseline and 6 months
Beck Depression Inventory-II (BDI-II)
Délai: Baseline and 6 months

The Beck Depression Inventory-II (BDI-II) is a 21-item self-report instrument designed to measure the severity of depressive symptoms over the past two weeks. Each item is rated on a 0 to 3 scale, and the total score ranges from 0 to 63.

The total BDI-II score is calculated by summing all 21 items, giving a range from 0 to 63. Common interpretive cut-offs are: minimal depression 0-13, mild 14-19, moderate 20-28, and severe 29-63

Baseline and 6 months
International Physical Activity Levels (IPAQ)
Délai: Baseline and 6 months

The International Physical Activity Questionnaire (IPAQ) is a self-report instrument designed to assess physical activity levels over the previous 7 days. It provides both a categorical score, classifying individuals as low, moderate, or high active, and a continuous score expressed as MET-minutes per week.

  • Categorical score: low, moderate, or high physical activity.
  • Continuous score: total physical activity expressed as MET-minutes/week.

The continuous score is calculated using standard MET values:

  • Walking = 3.3 METs.
  • Moderate activity = 4.0 METs.
  • Vigorous activity = 8.0 METs.
Baseline and 6 months
Prevention with Mediterranean Diet (PREDIMED)
Délai: Baseline and 6 months
The Prevention with Mediterranean Diet (PREDIMED) questionnaire is a 14-item tool designed to assess adherence to the Mediterranean diet. Each item is scored as 0 or 1, and the total score ranges from 0 to 14, with higher scores indicating greater adherence to the Mediterranean dietary pattern.
Baseline and 6 months

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Heart Rate
Délai: Continuously monitored from baseline to 6 months
Average heart rate measured through wearable sensors in beats per minute (bpm). Normal resting heart rate in adults is commonly about 60 to 100 bpm
Continuously monitored from baseline to 6 months
Heart Rate Variability (HRV)
Délai: Continuously monitored from baseline to 6 months
Nocturnal heart rate variability measured in milliseconds using wearable sensors.
Continuously monitored from baseline to 6 months
Body Weight
Délai: Baseline, every 2 weeks during the 6-month intervention period and 6 months
Change in body weight measured in kilograms (kg).
Baseline, every 2 weeks during the 6-month intervention period and 6 months
Body Mass Index (BMI)
Délai: Baseline and 6 months
adults, BMI is usually interpreted as follows: Underweight: below 18.5 Healthy weight: 18.5 to 24.9 Overweight: 25.0 to 29.9 Obesity: 30.0 or above
Baseline and 6 months
Nutritional Intake
Délai: Weekly monitoring from baseline to 6 months
Daily caloric, macronutrient, and micronutrient intake measured through in-app food diary records.
Weekly monitoring from baseline to 6 months
Mental Well-Being Weekly Check-in Scores
Délai: Weekly from baseline to 6 months
Weekly emotional well-being indicators measured through a 6-item Likert-scale in-app questionnaire assessing mood, calmness, energy, tension, and distress.
Weekly from baseline to 6 months

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Les enquêteurs

  • Chercheur principal: Gennaro Tartarisco, Institute for Biomedical Research and Innovation (IRIB)-National Reasearch Council (CNR)

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Publications générales

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

4 mai 2026

Achèvement primaire (Estimé)

30 novembre 2026

Achèvement de l'étude (Estimé)

30 mars 2027

Dates d'inscription aux études

Première soumission

19 mai 2026

Première soumission répondant aux critères de contrôle qualité

25 mai 2026

Première publication (Réel)

29 mai 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

29 mai 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

25 mai 2026

Dernière vérification

1 mai 2026

Plus d'information

Termes liés à cette étude

Termes MeSH pertinents supplémentaires

Autres numéros d'identification d'étude

  • CNR-IRIB-PRO-2026-004

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner